Biofrontera (NASDAQ: BFRI, BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, has closed its underwritten initial public offering of 3,600,000 units. According to the update, each unit consisted of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a per-unit public offering price of $5.00. The warrants have an exercise price of $5.00 per share and are exercisable for five years after the issuance date. In addition, the underwriters exercised in full their option to purchase up to an additional 540,000 warrants. Roth Capital Partners acted as Joint Book-Running Manager for the offering, which closed on Nov. 2, 2021.
To view the full press release, visit https://ibn.fm/izvQS
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy (“PDT”) and topical antibiotics. The company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information about the company, visit www.Biofrontera.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
